CME/CE
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
6:00
Chair: Komal Jhaveri, MD, FACP Faculty: Virginia Kaklamani, MD, DSc
Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy…